Pioneering Treatments for Paroxysmal Nocturnal Hemoglobinuria

By Staff Writer

December 11, 2023

Introduction

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder. It is characterised by chronic destruction of red blood cells and blood clots, primarily manifesting in fatigue and potentially leading to lifelong dependence on blood transfusions. The disease affects 10 to 20 people per million, primarily adults, with no association with sex, race, ethnicity, or geography. This Institute for Clinical and Economic Review (ICER) draft evidence report provides a comprehensive review of the latest research findings and treatments for PNH.

The Current State of PNH Treatment

The treatment landscape for PNH has been transformed by the advent of C5 inhibitor therapy. This treatment significantly reduces intravascular hemolysis, thrombosis, and death, bringing life expectancies closer to age-matched controls. FDA-approved intravenous C5 inhibitors, such as eculizumab and ravulizumab, are recommended for symptomatic PNH patients. Ravulizumab is often preferred due to its longer half-life and lower costs.

Pegcetacoplan – A New Hope

Pegcetacoplan, another FDA-approved treatment, has shown promise. Unlike C5 inhibitors, pegcetacoplan prevents both intra and extravascular hemolysis. However, it is largely used only for patients who have clinically significant extravascular hemolysis (EVH) while on a stable C5 inhibitor regimen.

Iptacopan and Danicopan – The Next Generation of PNH Treatments

Two first-in-class proximal complement inhibitors, Iptacopan and Danicopan, are currently under consideration for FDA approval. Iptacopan, an oral Factor B inhibitor, is being considered for all PNH patients, while Danicopan, an oral Factor D inhibitor, is being considered as an add-on therapy for treatment-experienced patients with clinically significant EVH. Both drugs display promising early trial results. However, we need more research to comprehend their long-term benefits and safety profiles fully. 

The Cost-Effectiveness of New Treatments

A recent study examined the cost-effectiveness of iptacopan and add-on danicopan in treatment-experienced patients with PNH. The study found that treatment with iptacopan resulted in small gains in quality-adjusted life years (QALYs) and equivalent life years (evLYs), and would be cost-saving compared to ravulizumab. However, treatment with add-on danicopan resulted in more costs, with an incremental cost-effectiveness ratio of $9,462,000 per QALY or evLY gained.

Conclusion

New therapies like iptacopan and danicopan are changing the treatment landscape for PNH, a rare blood disorder. We need to investigate their long-term benefits and safety profiles further. Their cost-effectiveness will depend on their price as per this ICER report.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.